All of the known prognostic markers such as tumor size, nodal involvement, triple negativity, estrogen receptor expression, and Her2/neu expression were compensated for, or even reversed by, treatment [31] after up to ten years of follow-up. The gene discussed is ERBB2; the disease is neoplasm.